WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

2026-02-03 - 05:38

SHANGHAI, Feb. 3, 2026 /PRNewswire/ — WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases. Under the